[The double messages about atenolol must be an issue for the SBU board].
Werkö
Lars
L
SBU, Stockholm.
Enkvist
Christer
C
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use*; D032921:Consensus; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D015201:Meta-Analysis as Topic; D017410:Practice Guidelines as Topic; D017594:Publication Bias; D013548:Sweden
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001262:Atenolol